新股消息 | 华芢生物通过港交所聆讯 仅有两款核心产品

Core Viewpoint - Huazhan Biotechnology (Qingdao) Co., Ltd. has passed the listing hearing on the Hong Kong Stock Exchange, with Huatai International and CITIC Securities as joint sponsors [1] Company Overview - Established in 2012, the company is a biopharmaceutical firm based in China, focusing on developing therapies, particularly protein drugs targeting medical needs and market opportunities [3] - The company's main focus is on discovering, developing, and commercializing wound healing therapies, currently centered on platelet-derived growth factor (PDGF) drugs [3] Product Pipeline - As of the last feasible date (December 5, 2025), the company has two core products in its pipeline: 1. Pro-101-1 for treating deep second-degree burns, which has completed statistical analysis of Phase IIb clinical trial data 2. Pro-101-2 for treating diabetic foot ulcers, currently in Phase II clinical trials [3][5] - The company also has eight other candidate products in its pipeline [3] Clinical Trial Progress - For Pro-101-1, there is no statistically significant difference between the treatment and placebo groups based on FAS, leading to an extension of the evaluation of Phase IIb results and the initiation of Phase IIIa trials [4] - If the Phase IIIa trial results are unsatisfactory, the company may not receive approval to proceed to Phase IIIb trials, significantly limiting the market potential for Pro-101-1 [4] Financial Performance - The company reported losses of approximately 105.19 million RMB, 212.25 million RMB, and 134.47 million RMB for the fiscal years ending in 2023, 2024, and the nine months ending September 30, 2025, respectively [5][6] - Revenue for the fiscal year 2023 was 472 thousand RMB, with a gross profit of 217 thousand RMB [6]